Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Aging with multiple sclerosis: prevalence and profile of cognitive impairment.

Branco M, Ruano L, Portaccio E, Goretti B, Niccolai C, Patti F, Chisari C, Gallo P, Grossi P, Ghezzi A, Roscio M, Mattioli F, Bellomi F, Simone M, Viterbo RG, Amato MP.

Neurol Sci. 2019 Aug;40(8):1651-1657. doi: 10.1007/s10072-019-03875-7. Epub 2019 Apr 23.

PMID:
31011932
2.

Altered bodily self-consciousness in multiple sclerosis.

Nava E, Mattioli F, Gamberini C, Stampatori C, Bellomi F, Turati C, Capra R, Bolognini N.

J Neuropsychol. 2018 Sep;12(3):463-470. doi: 10.1111/jnp.12134. Epub 2017 Sep 10.

PMID:
28891265
3.

Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.

Mattioli F, Bellomi F, Stampatori C, Provinciali L, Compagnucci L, Uccelli A, Pardini M, Santuccio G, Fregonese G, Pattini M, Allegri B, Clerici R, Lattuada A, Montomoli C, Corso B, Gallo P, Riccardi A, Ghezzi A, Roscio M, Tola MR, Calanca C, Baldini D, Trafficante D, Capra R.

Front Behav Neurosci. 2016 Feb 23;10:28. doi: 10.3389/fnbeh.2016.00028. eCollection 2016.

4.

Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.

Mattioli F, Stampatori C, Bellomi F, Scarpazza C, Capra R.

PLoS One. 2015 Jul 6;10(7):e0131803. doi: 10.1371/journal.pone.0131803. eCollection 2015.

5.

Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.

Mattioli F, Bellomi F, Stampatori C, Capra R, Miniussi C.

Mult Scler. 2016 Feb;22(2):222-30. doi: 10.1177/1352458515587597. Epub 2015 May 26.

PMID:
26014600
6.

A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study.

Mattioli F, Stampatori C, Bellomi F, Danni M, Compagnucci L, Uccelli A, Pardini M, Santuccio G, Fregonese G, Pattini M, Allegri B, Clerici R, Lattuada A, Montomoli C, Corso B, Capra R.

Front Neurol. 2015 Jan 13;5:278. doi: 10.3389/fneur.2014.00278. eCollection 2014.

7.

Assessing executive function with the D-KEFS sorting test: normative data for a sample of the Italian adult population.

Mattioli F, Stampatori C, Bellomi F, Scarpazza C, Galli P, Guarneri C, Corso B, Montomoli C, Niccolai C, Goretti B, Amato MP, Riboni E, Tomasina CD, Falautano M, Capra R.

Neurol Sci. 2014 Dec;35(12):1895-902. doi: 10.1007/s10072-014-1857-7. Epub 2014 Jul 6.

PMID:
24998015
8.

Patterns of regional gray matter and white matter atrophy in cortical multiple sclerosis.

Parisi L, Rocca MA, Mattioli F, Riccitelli GC, Capra R, Stampatori C, Bellomi F, Filippi M.

J Neurol. 2014 Sep;261(9):1715-25. doi: 10.1007/s00415-014-7409-5. Epub 2014 Jun 22.

PMID:
24952616
9.

Depression, disability and cognitive impairment in multiple sclerosis: a cross sectional Italian study.

Mattioli F, Bellomi F, Stampatori C, Parrinello G, Capra R.

Neurol Sci. 2011 Oct;32(5):825-32. doi: 10.1007/s10072-011-0624-2. Epub 2011 May 19.

PMID:
21594654
10.

Neuropsychological rehabilitation in adult multiple sclerosis.

Mattioli F, Stampatori C, Bellomi F, Capra R, Rocca M, Filippi M.

Neurol Sci. 2010 Nov;31(Suppl 2):S271-4. doi: 10.1007/s10072-010-0373-7. Review.

PMID:
20640467
11.

Natalizumab efficacy on cognitive impairment in MS.

Mattioli F, Stampatori C, Bellomi F, Capra R.

Neurol Sci. 2011 Jan;31 Suppl 3:321-3. doi: 10.1007/s10072-010-0351-0.

PMID:
20535512
12.

Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.

Sbardella E, Tomassini V, Gasperini C, Bellomi F, Cefaro LA, Morra VB, Antonelli G, Pozzilli C.

BMC Neurol. 2009 Oct 13;9:54. doi: 10.1186/1471-2377-9-54.

13.

Measurement of the sensitivity of different commercial assays in the diagnosis of CMV infection in pregnancy.

Gentile M, Galli C, Pagnotti P, Di Marco P, Tzantzoglou S, Bellomi F, Ferreri ML, Selvaggi C, Antonelli G.

Eur J Clin Microbiol Infect Dis. 2009 Aug;28(8):977-81. doi: 10.1007/s10096-009-0738-0. Epub 2009 Apr 10.

PMID:
19360443
14.

Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.

Bellomi F, Bramanti P, Trojano M, Scagnolari C, Muto A, Sessa E, La Volpe V, Russo P, Antonelli G.

J Immunoassay Immunochem. 2009;30(1):40-50. doi: 10.1080/15321810802569857.

PMID:
19117201
15.

Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients.

Riva E, Maggi F, Abbruzzese F, Bellomi F, Giannelli G, Picardi A, Scagnolari C, Folgori A, Spada E, Piccolella E, Dianzani F, Antonelli G; Acute Hepatitis C Italian Study Group.

Med Microbiol Immunol. 2009 Feb;198(1):13-8. doi: 10.1007/s00430-008-0099-9. Epub 2008 Aug 12.

PMID:
18696111
16.

Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis.

Bellomi F, Muto A, Palmieri G, Focaccetti C, Dianzani C, Mattei M, Jaber A, Antonelli G.

New Microbiol. 2007 Jul;30(3):241-6.

17.

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.

Bruno R, Sacchi P, Scagnolari C, Torriani F, Maiocchi L, Patruno S, Bellomi F, Filice G, Antonelli G.

Aliment Pharmacol Ther. 2007 Aug 1;26(3):369-76.

18.

Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals.

Turriziani O, Bucci M, Stano A, Scagnolari C, Bellomi F, Fimiani C, Mezzaroma I, D'Ettorre G, Brogi A, Vullo V, Antonelli G.

J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):518-24.

PMID:
17224845
19.

Expression of biomarkers of interferon type I in patients suffering from chronic diseases.

Scagnolari C, Bellomi F, Trombetti S, Casato M, Carlesimo M, Bagnato F, Lavolpe V, Bruno R, Millefiorini E, Antonelli L, Girardi E, Turriziani O, Antonelli G.

Clin Exp Immunol. 2007 Feb;147(2):270-6.

20.

The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a T-lymphoblastoid cell line.

Turriziani O, Pagnotti P, Pierangeli A, Focher F, Baranello C, Bellomi F, Falasca F, Morgan J, Schuetz JD, Antonelli G.

AIDS Res Hum Retroviruses. 2006 Oct;22(10):960-7.

PMID:
17067265
21.

A novel assay to detect low-titred antibodies to interferon beta in multiple sclerosis patients.

Di Marco P, Pagnotti P, Bellomi F, De Vito G, Sessa E, Bagnato F, Scagnolari C, Bramanti P, Antonelli G.

New Microbiol. 2006 Jan;29(1):11-8.

PMID:
16608120
22.

Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.

Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, Clementi M, Dianzani F, Antonelli G.

Antivir Ther. 2004 Dec;9(6):1003-11.

PMID:
15651759
23.

P-glycoprotein expression affects the intracellular concentration and antiviral activity of the protease inhibitor saquinavir in a T cell line.

Maffeo A, Bellomi F, Solimeo I, Bambacioni F, Scagnolari C, De Pisa F, Dupuis ML, Cianfriglia M, Antonelli G, Turriziani O.

New Microbiol. 2004 Apr;27(2 Suppl 1):119-26.

PMID:
15646074
24.

Neutralizing antibodies against endogenous interferon in myasthenia gravis patients.

Bagnato F, Clemenzi A, Scagnolari C, Strizzi L, Di Pasquale A, Bellomi F, Di Marco P, Antonelli G, Antonini G.

Eur Cytokine Netw. 2004 Jan-Mar;15(1):24-9.

25.

Cellular issues relating to the resistance of HIV to antiretroviral agents.

Turriziani O, Scagnolari C, Bellomi F, Solimeo I, Focher F, Antonelli G.

Scand J Infect Dis Suppl. 2003;106:45-8. Review.

PMID:
15000583
26.

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years.

Bellomi F, Scagnolari C, Tomassini V, Gasperini C, Paolillo A, Pozzilli C, Antonelli G.

J Neurol Sci. 2003 Nov 15;215(1-2):3-8.

PMID:
14568120
27.

P-glycoprotein expression by peripheral blood mononuclear cells from human immunodeficiency virus-infected patients is independent from response to highly active antiretroviral therapy.

Agrati C, Poccia F, Topino S, Narciso P, Selva C, Pucillo LP, D'Offizi G, Antonelli G, Bellomi F, Turriziani O, Bambacioni F.

Clin Diagn Lab Immunol. 2003 Jan;10(1):191-2. No abstract available.

28.

Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.

Scagnolari C, Casato M, Bellomi F, De Pisa F, Turriziani O, Coviello R, Pirro MR, Dianzani F, Antonelli G.

Clin Diagn Lab Immunol. 2003 Jan;10(1):70-7.

29.

Selection of a T-cell line resistant to stavudine and zidovudine by prolonged treatment with stavudine.

Turriziani O, Scagnolari C, Bambacioni F, Bellomi F, Focher F, Gentile M, Antonelli G.

Antivir Ther. 2002 Jun;7(2):105-11.

PMID:
12212922
30.

Proteolytic balance in patients with multiple sclerosis during interferon treatment.

Giannelli G, De Marzo A, Scagnolari C, Bergamini C, Fransvea E, Bagnato F, Bellomi F, Millefiorini E, Gasperini C, Antonaci S, Antonelli G.

J Interferon Cytokine Res. 2002 Jun;22(6):689-92.

PMID:
12162880
31.

A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.

Bagnato F, Pozzilli C, Scagnolari C, Bellomi F, Pasqualetti P, Gasperini C, Millefiorini E, Galgani S, Spadaro M, Antonelli G.

Neurology. 2002 May 14;58(9):1409-11.

PMID:
12011292
32.

Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations.

Scagnolari C, Bellomi F, Turriziani O, Bagnato F, Tomassini V, Lavolpe V, Ruggieri M, Bruschi F, Meucci G, Dicuonzo G, Antonelli G.

J Interferon Cytokine Res. 2002 Feb;22(2):207-13.

PMID:
11911803

Supplemental Content

Loading ...
Support Center